Here’s what you need to know.
1. Allergan received the rights to preclinical compounds ABI-M201 and ABI-M301 targeting ulcerative colitis and Crohn’s disease. Allergan also received rights to two compounds targeting various forms of irritable bowel syndrome.
2. Allergan will pay $50 million to Assembly. Assembly will also hold various different types of royalties.
3. The transaction should close in the first quarter of 2017.
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Bitman Stewart of Digestive Care
Integrated Endoscopy seeks $4.4M for executive compensation: 3 key notes
Hallmark Health Medical Associates names gastroenterologist Dr. Michael Newman president: 3 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.